Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation

Fan Liao(Hope Center for Neurological Disorders), David M. Holtzman(Washington University in St. Louis), Paul Lerner(Harvard University), Zachary K. Sweeney(Denali Therapeutics (United States)), Eloïse Hudry(Novartis (Switzerland)), Katheryn B. Lefton(Hope Center for Neurological Disorders), Cheryl E. G. Leyns(Hope Center for Neurological Disorders), Monica Xiong(Sunesis (United States)), Nga Bien‐Ly(Alector (United States)), Jason D. Ulrich(Hope Center for Neurological Disorders), Jennifer A. Getz(Denali Therapeutics (United States)), Kirk R. Henne(Denali Therapeutics (United States)), Bradley T. Hyman(Harvard University), Javier Remolina Serrano(Hope Center for Neurological Disorders), Jennifer Keyser(Hope Center for Neurological Disorders), Ryan J. Watts(Unknown), Mary Beth Finn(Hope Center for Neurological Disorders), Rosa Hoyle(Hope Center for Neurological Disorders), Mark S. Dennis(Denali Therapeutics (United States)), Yin Zhang(Shantou University), Aimin Li(City Of Hope National Medical Center), Hong Jiang(The University of Texas at Arlington), Jing Guo(Qingdao University), Adam P. Silverman(Northwell Health), Gilbert Gallardo(Hope Center for Neurological Disorders), Grace O. Robinson(Hope Center for Neurological Disorders), Patrick M. Sullivan(Veterans Health Administration)
Journal of Clinical Investigation
March 30, 2018
Cited by 186


Related Papers